Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.
Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.
Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.
Jan Willem Popma
Director, Ace Pharmaceuticals BV
Talk to the deal team
Niels Vermuë
Oaklins Netherlands
Related deals
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreHe-Man Dual Controls has been acquired by Lagercrantz UK Limited
Lagercrantz UK Limited has acquired 100% of the shares in HM Holding Limited (He-Man Dual Controls), a leader in supplemental control systems for vehicles.
Learn moreManolete Partners plc has completed a successful debt refinancing
Manolete Partners plc has signed a new revolving credit facility (RCF) with its existing provider, HSBC. The new RCF provides Manolete with the same level of facility as the previous arrangement, at US$22.6 million (£17.5 million), but with a reduced margin and lower non-utilization fee. The facility has a term of 3.25 years, with the option to extend for an additional year on the same terms.
Learn more